According to Persistence Market Research, the global home infusion therapy market was valued at US$35 billion in 2026 and is projected to reach US$62.1 billion by 2033. This is attributed to the therapy’s ability to manage gastrointestinal disorders, diabetes, cancer-related pain, cystic fibrosis, chronic dehydration, as well as a wide range of acute and chronic illnesses requiring precise, timely drug delivery.
Growing Burden of Chronic Diseases is Fueling Long-Term Demand
The increasing prevalence of chronic diseases is one of the strongest factors driving the home infusion therapy market. Patients diagnosed with cancer, diabetes, immune disorders, gastrointestinal diseases, heart failure, and severe infections often require long-term intravenous treatment that traditionally necessitated repeated hospital visits.
According to the World Health Organization (WHO), noncommunicable diseases (NCDs) cause approximately 41 million deaths annually, accounting for nearly 74% of all global deaths. Cardiovascular diseases alone account for about 17.9 million deaths each year, followed by cancer (10 million), chronic respiratory diseases (4 million), and diabetes (2 million, including kidney disease caused by diabetes).
As these chronic conditions become more prevalent, healthcare settings are constantly adopting home infusion therapy to reduce unnecessary hospital admissions, lower healthcare costs, and improve patient comfort. Home-based treatment enables patients to continue receiving complex therapies while maintaining their daily routines and reducing exposure to hospital-acquired infections.
An Aging Population is Accelerating the Shift Toward Home Healthcare
Demographic changes are creating long-term opportunities for the home infusion therapy market. According to the World Health Organization, one in every six people worldwide will be aged 60 years or older by 2030, with the global elderly population increasing from 1 billion in 2020 to 1.4 billion by 2030. By 2050, this population is expected to exceed 2.1 billion.
Older adults frequently require prolonged treatment for multiple chronic illnesses, including cancer, cardiovascular diseases, neurological disorders, and immune deficiencies that often involve intravenous medications or nutritional support. Home infusion therapy minimizes the physical burden associated with frequent hospital visits while allowing elderly patients to receive treatment in familiar surroundings, thereby improving quality of life and reducing hospital occupancy.
Surging Diabetes Cases Are Boosting the Need for Home Infusion Services
Diabetes continues to expand the patient population requiring infusion-based care. According to the U.S. Centers for Disease Control and Prevention (CDC), approximately 38.4 million Americans, representing 12.0% of the U.S. population, are living with diabetes, while an additional 115.2 million adults have prediabetes.
Patients with diabetes are at increased risk of severe infections, kidney disease, diabetic foot complications, and other conditions requiring intravenous antibiotics, hydration therapy, and nutritional support. As diabetes prevalence continues to rise worldwide, demand for professionally managed home infusion services is expected to grow steadily.
Oncology Care is Creating New Opportunities for Home Infusion Providers
The rapid expansion of oncology care is creating significant opportunities for home infusion providers. According to the International Agency for Research on Cancer (IARC), a specialized agency of WHO, there were approximately 20 million new cancer cases and 9.7 million cancer-related deaths globally in 2022.
Cancer patients often require repeated chemotherapy, immunotherapy, supportive hydration, pain management, and parenteral nutrition over extended treatment periods. Delivering these therapies at home reduces hospital visits, minimizes travel-related stress, and enables healthcare providers to optimize hospital resources while maintaining continuity of care.
Novel Technology is Making Home Infusion Therapy Safe and Efficient
The widespread adoption of home infusion therapy has been made possible through technological innovation. Modern infusion pumps have become smaller, programmable, and highly accurate, thereby reducing medication errors while improving treatment precision. Connected infusion devices can transmit treatment data directly to healthcare providers, enabling remote monitoring and timely intervention if complications arise.
Telehealth consultations, wearable monitoring devices, and digital health platforms are further strengthening communication between physicians, nurses, pharmacists, caregivers, and patients. These technologies are enhancing patient safety while increasing physician confidence in home-based treatment models.
Healthcare Institutions Are Prioritizing Cost-Effective Care Models
Healthcare expenditure continues to increase globally, encouraging governments and insurers to invest in alternative care delivery models. Home infusion therapy significantly lowers treatment costs by reducing inpatient admissions, shortening hospital stays, and decreasing demand for hospital infrastructure.
Patients also benefit from lower travel expenses, reduced caregiver burden, and fewer disruptions to work and family life. These economic advantages are encouraging healthcare providers and insurance organizations to integrate home infusion therapy into long-term disease management programs.
Government Support and Reimbursement Policies are Boosting Home Infusion Care
- CMS Continues Broadening Hospital-at-Home Programs
Government agencies are actively supporting the expansion of home healthcare services. For instance, in March 2026, the U.S. Centers for Medicare & Medicaid Services (CMS) released expanded data from its Acute Hospital Care at Home (AHCAH) initiative, covering nearly five years of program implementation.
The initiative, originally launched during the COVID-19 pandemic, has been extended through 2030, demonstrating continued federal support for hospital-level care delivered in patients' homes. The aforementioned program has shown that appropriately selected patients can safely receive hospital-grade treatment, including infusion therapies, while maintaining high standards of clinical care outside traditional hospital settings.
- Medicare Reimbursement is Improving Patient Access
The Centers for Medicare & Medicaid Services (CMS) continues to strengthen access to home infusion services through the Medicare Home Infusion Therapy Benefit. It provides reimbursement for professional nursing services, patient education, remote monitoring, and associated home infusion care for eligible beneficiaries.
CMS also regularly updates directories of certified Home Infusion Therapy suppliers and publishes utilization reports that improve transparency as well as patient access. Stable reimbursement policies are encouraging healthcare providers to expand their home infusion programs while increasing confidence among patients, physicians, and payers.
- Improved Quality Standards Are Enhancing Patient Confidence
Quality assurance is becoming very important as home healthcare expands. For example, in 2026, CMS implemented OASIS-E2, an updated national quality reporting framework for Medicare-certified home health agencies.
The revised assessment improves standardized patient evaluations, strengthens outcome measurement, and enhances consistency across home healthcare providers. Similar high quality standards are expected to improve patient safety, support clinical decision-making, and reinforce trust in home infusion therapy as a reliable alternative to hospital-based care.
North America Leads While Asia Pacific Emerges as the Fastest-Growing Market
North America continues to dominate the home infusion therapy market due to advanced healthcare infrastructure, widespread adoption of specialty biologics, favorable reimbursement policies, and well-established home healthcare networks. The U.S. has also expanded hospital-at-home programs that support home-based infusion services for eligible patients. For instance,
- In May 2025, ICU Medical and Otsuka Pharmaceutical Factory formed Otsuka ICU Medical LLC through a joint venture. The companies strengthened IV solutions manufacturing, improved supply chain resilience, and expanded access to advanced infusion products across North America.
North America has a large population of patients with chronic diseases such as cancer, diabetes, immune disorders, and infections that require long-term infusion therapies.
Home Infusion Therapy is Changing the Future of Patient-Centered Care
Home infusion therapy is reshaping the future of healthcare delivery by moving clinically appropriate treatments beyond hospital walls. Rising chronic disease prevalence, an aging global population, increasing cancer incidence, and growing diabetes cases are creating sustained demand for safe, efficient, and cost-effective home-based infusion services.
Technological advancements, expanding Medicare reimbursement, supportive government initiatives such as CMS's Acute Hospital Care at Home program, and strengthened quality standards are accelerating market growth. As healthcare systems worldwide focus on reducing costs while improving patient outcomes, home infusion therapy is expected to become a cornerstone of modern healthcare, offering a scalable solution that combines clinical excellence with patient convenience.
